Drug intelligence / Profile preview

EO-0408

Development stage: Preclinical
Lead developer: Emmetrope Ophthalmics
Administration: Ophthalmic

Overview

EO-0408 is an investigational drug being developed for the treatment of glaucoma. It is currently in preclinical development and is associated with Emmetrope Ophthalmics. The specific mechanism of action, modality, and molecular target have not been disclosed in public sources as of April 2025. Its development status indicates it has not yet entered clinical trials beyond the preclinical stage.

Other names: EO-0408EO0408EO 0408

Beyond the preview

Go deeper on EO-0408.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EO-0408.

Explore the full profile